Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...
Got interesting news to share involving schools and universities associated with Churches of Christ? We welcome readers’ tips and ideas. Email us at [email protected]. Abilene Christian University in ...
Exercise is guideline-recommended for patients with osteoarthritis of the knee, although comparative benefits from specific forms of exercise are less certain. This literature review and meta-analysis ...
Previous mega blockbusters took years to reach their peak sales. Lilly’s tirzepatide franchise is on course to exceed them just a few years in. Eli Lilly is rewriting the rules of pharma. Not only did ...
New subgroup analysis from the Phase 3 monarchE trial that explores outcomes by nodal status for Verzenio plus endocrine therapy in HR+, HER2– high-risk early breast cancer INDIANAPOLIS, Nov. 24, 2025 ...
INDIANAPOLIS, Nov. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio ...
Eli Lilly is upgraded to a "Strong Buy" due to 54% revenue growth, driven by Zepbound and Mounjaro's success in obesity and T2D. The company is expanding its pipeline with Orforglipron [oral GLP-1 ...
Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. The latest high-profile crossovers—which include a starry TV partnership and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback